Ehave is a healthcare company focusing on next-generation digital solutions for stakeholders in the medical cannabis and mental health sectors. Ehave has a health informatics platform that captures high-quality, objective user data. It is also building a comprehensive platform where powerful, condition-specific applications can be conceptualized, built, clinically validated, and also deployed. Ehave are teaming up with researchers around the world to explore hallucinogen-persisting perception disorder (HPPD).
Ehave
Ehave aims to bridge the substantial information gap in healthcare to benefit stakeholders with improved data collection and analysis, and simultaneously enable the deployment of new digital assessment and remediation tools to empower users and improve the health and wellness of the patients.
“Ehave – Business, Laboratory, Research, Clinical & Pharmaceutical”
Activities
B2B
B2C
Digital Health / Software / App
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures (Yahoo Finance, 08 December 2021)Mycotopia and Ei.Ventures announced the signing of an LOI to explore a merger and the formation of PSLY.COM, a $360 Million transaction, and will apply to list shares on NASDAQ; Ehave plans to spin out 30%.
Ehave Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research (GlobeNewswire, 01 June 2022)